FDA schedules joint advisory committee meeting to consider first over-the-counter birth control pill

The FDA has set a date to review what could become the first over-the-counter birth control pill approved for use in the US.

HRA Pharma, recently acquired by Dublin-based Perrigo, filed back in July to make its daily progestin-only Opill available without a prescription. On Monday, the regulatory agency scheduled a joint meeting of its Nonprescription Drugs Advisory Committee and the Obstetrics, Reproductive and Urologic Drugs Advisory Committee to review the application on Nov. 18 from 9 am to 5:30 pm ET.